https://www.biopharmadive.com/news/fda-fibrogen-advisers-vote-roxadustat-anemia/603458/
FDA advisers push back on FibroGen anemia drug | BioPharma Dive
Safety worries led to a near-unanimous vote against roxadustat in kidney disease patients, dimming the approval chances of what would be the first pill to...
drug biopharma divepush back
https://www.biopharmadive.com/news/novavax-covid-vaccine-fda-advisers-vote-recommend/625050/
FDA advisers back Novavax's latecomer COVID-19 vaccine | BioPharma Dive
fda advisersbacknovavaxcovid